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 The Community Pharmacy EC service helps meet the EC needs of women of any
age, despite originally being targeted at teenagers.
 The reasons for attending an EC consultation vary with age, and age-targeted
actions are needed to increase awareness of contraception use in all age groups.
 Results support expansion of the role of the community pharmacists to include
provision of regular contraception.
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Abstract
Background 
Access to Emergency Contraception (EC) has been a core component of attempts to 
address high teenage pregnancy rates in Wales. A national service was commissioned in 
2011, allowing supply of EC free of charge from community pharmacies (CPs). This study 
investigated five years of the EC service, to describe its use and investigate changes in the 
pattern of use over time.
Methods 
Secondary analyses of data from all NHS funded CP EC consultations in Wales between 1 
August 2012 and 31 July 2017 (n=181,359).  Data comprised standardized clinical and 
demographic information, in the form of pre-defined service user responses, submitted for 
reimbursement by CPs.
Results 
Overall service provision remained relatively consistent over the study period, with women 
between 13 and 59 years of age accessing the service. An association was observed 
between the time since unprotected sexual intercourse and the day on which the service 
was accessed (X2(18) = 16292.327, p<0.001). Almost half (47.9%) of requests were 
because no contraception had been used, with a strong and positive association for 
teenagers and women over 40. A statistically significant and increasing percentage of 
consultations were accompanied by further sexual health advice (r=0.7, p<0.01). 
Conclusions 
Access to EC through CPs is contributing to reducing teenage conceptions and termination 
rates. However, action is needed to increase contraception use in all age groups. Reduced 
availability of CP services on Sundays is a barrier to timely EC access.  Findings support an 
expanded role for community pharmacists in provision of regular contraception.
Key messages
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Introduction
Emergency contraception (EC) is used to prevent pregnancy following unprotected sexual 
intercourse (UPSI) or contraceptive failure.  In the United Kingdom (UK) two methods of EC 
are in common use: insertion of an intrauterine device (IUD) within five days of UPSI; and 
the administration of an emergency contraceptive pill. (1) Two types of licensed EC pill are 
currently available. Preparations containing levonorgestrel, licensed for use up to 72 hours 
following UPSI, have been available since 2000, whereas ulipristal acetate 30mg tablet 
(EllaOne®), for use within 120 hours of UPSI, has been available since 2009. (2,3) Initially 
EC pills were licensed in the UK as prescription only medicines (POMs), requiring a 
prescription from general practitioners (GPs), or supplied by family planning or accident and 
emergency services.  
In the early 2000s, in an attempt to improve access to EC, NHS bodies across the UK, 
began making provision for POM levonorgestrel to be supplied from community pharmacies 
(CPs) without prescription using patient group directions (PGDs). (4) Subsequently, 
levonorgestrel was reclassified as a pharmacy medicine, to allow it to be sold ‘over-the-
counter’ (OTC) from CPs. However, the high cost of OTC relative to POM preparations, and 
licensing restrictions which prevented pharmacists selling EC to girls under 16, remained 
barriers to wider access and NHS funded PGD schemes persisted. (5) 
In 2011, the Welsh Government directed local health boards to commission a national EC 
service from CPs allowing levonorgestrel to be obtained by women and girls from the age of 
13 free of charge under a PGD. (6) In April 2015, the service was extended to allow ulipristal 
acetate to be supplied between 72 and 120 hours after UPSI. The arrangements aimed to 
widen access to EC and increase the provision of sexual health advice amongst sexually 
active women. By 2017, 76% of CPs in Wales (544/716) were providing the service. (7)  
Most previous research has focused on OTC sales of EC, rather than supply under a PGD 
(8-12).  In general, studies have been small scale evaluations of pilot schemes, they have 
however, consistently identified pharmacy services promote access to EC and are highly 
acceptable to service users, with many reporting CPs as the preferred route of access. 
There has to date been no large scale, longitudinal evaluation of EC provision by CPs to 
explore whether the benefits identified in smaller studies are maintained over time. The aim 
of this study was twofold: first to describe the CP EC use in Wales between 2012 and 2017, 
and secondly to investigate changes in the pattern of EC use over time.
Methods
Figure 1 presents an overview of the study methodology. (13)
Study design and setting
Secondary analyses of data from all NHS funded EC consultations taking place in CPs in 
Wales between 1 August 2012 and 31 July 2017 (n = 181,359) was undertaken.  Data were 
obtained from the NHS Wales Shared Services Partnership from details of EC service 
consultations, submitted by CPs for reimbursement. Data contained standardised clinical 
and demographic information, in the form of pre-defined responses recorded by 
pharmacists.
As there were no identifiers that could link the information to an individual in the data set, this 
study required no ethical approval. (14)
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Measures
Our primary outcome was the number of CP EC consultations over time.  Secondary 
outcomes were consultation outcome (i.e. EC supplied or not, levonorgestrel versus ulipristal 
acetate); the rate of EC use by age group; EC access by day of week; time since UPSI; 
reason for requesting EC and regular use of contraception by service users, defined in the 
service specification as the use of any form of prescribed contraception including oral 
contraception, contraceptive patch, long acting reversible contraception, or intrauterine 
device or system; and how these changed over time. 
Statistical analyses
Data were exported to IBM SPSS® v23 for analysis; a random 10% manual validation check 
was conducted independently by two researchers for quality assurance of the data transfer 
process. No discrepancies were identified. Secondary data analysis was carried out using 
Microsoft Excel® and IBM SPSS® v23 to obtain descriptive statistics and undertake more 
detailed statistical comparisons.  Scatter plots and line graphs with 95% confidence intervals 
were used to assess linearity between time and EC service use as well as outcomes.  
Pearson’s chi-squared tests were used to determine if there were any statistically significant 
associations between variables (p<0.05), and the distribution of standardized residuals (z-
scores) to determine the strength of the associations.
Patient Involvement
Patients were not involved in the design or conduct of this study. 
Results
Overall characteristics of the population using the EC service for all 181,359 recorded 
consultations between 1 August 2012 and 31 July 2017 are presented in Table 1. There was 
evidence of a decline in the absolute number of EC requests over the study period (r =-0.41, 
p = 0.001) (Supplementary Figure 1). The median age of service users was 25, range 13-59, 
interquartile range 19-30 (data available for n=175,460 consultations). After age data were 
standardized per age group population using data for estimated population in Wales (15), 
the highest rate of consultations was noted for 16-19-year-olds (at 5.5 consultations per 100 
population) (Table 2). 
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Table 1 Overall characteristics of the population using the community pharmacy Emergency Contraception (EC) service during the 5-year 
study period 1st August 2012 – 31st July 2017 (total consultations n=181,359).
2012-13 2013-14 2014-15 2015-16 2016-17 Total
n (%)* n (%)* n (%)* n (%)* n (%)* n (%)*
Age group 13-15 1,312 (3.5) 1,223 (3.3) 883 (2.5) 878 (2.5) 786 (2.2) 5,082 (2.8)
16-19 8,807 (23.8) 8,958 (23.9) 8,064 (22.6) 7,849 (22.0) 6,806 (19.2) 40,484 (22.3)
20-24 11,342 (30.6) 11,219 (29.9) 10,438 (29.3) 10,042 (28.1) 8,754 (24.7) 51,795 (28.6)
25-29 6,722 (18.1) 6,844 (18.3) 6,912 (19.4) 6,843 (19.2) 6,264 (17.6) 33,585 (18.5)
30-39 6,573 (17.7) 6,835 (18.3) 6,945 (19.5) 6,935 (19.4) 6,692 (18.8) 33,980 (18.7)
40+ 2,142 (5.8) 2,147 (5.7) 2,213 (6.2) 2,116 (5.9) 1,916 (5.4) 10,534 (5.8)
Not recorded 180 (0.5) 190 (0.5) 162 (0.5) 1,069 (3.0) 4,298 (12.1) 5,899 (3.3)
Regular contraception use Yes 16,376 (44.2) 15,500 (41.4) 14,049 (39.4) 13,190 (36.9) 12,029 (33.9) 71,144 (39.2)
No 20,702 (55.8) 21,916 (58.6) 21,568 (60.6) 22,542 (63.1) 23,487 (66.1) 110,215 (60.8)
Reason for EC request Failure of barrier contraception 16,983 (45.8) 16,505 (44.1) 15,160 (42.6) 14,677 (41.1) 13,448 (37.9) 76,773 (42.3)
No contraception used 17,093 (46.1) 17,878 (47.8) 17,282 (48.5) 17,141 (48.0) 17,642 (49.7) 87,036 (47.9)
Missed contraception 3,002 (8.1) 3,033 (8.1) 3,175 (8.9) 3,904 (10.9) 3,667 (10.3) 16,781 (9.3)
Other 0 (0.0) 0 (0.0) 0 (0.0) 10 (0.0) 759 (2.1) 769 (0.4)
0-24 25,894 (69.8) 25,851 (69.1) 24,107 (67.7) 23,561 (65.9) 23,038 (64.9) 122,451 (67.5)
25-48 8,955 (24.2) 9,045 (24.2) 8,871 (24.9) 8,917 (25.0) 8,754 (24.6) 44,542 (24.6)
Time since UnProtected 
Sexual Intercourse (UPSI)
49+ 2,229 (6.0) 2,520 (6.7) 2,639 (7.4) 3,254 (9.1) 3,724 (10.5) 14,366 (6.4)
Levonorgestrel 1.5mg tablet (Levonelle®) 36,090 (97.3) 36,426 (97.4) 34,599 (97.1) 34,269 (95.9) 34,012 (95.8) 175,396 (96.7)
Ulipristal Acetate 30mg Tablet (EllaOne®) - - - - 188 (0.5) 726 (2.0) 877 (2.5) 1,791 (0.9)
Medication provided 
(EllaOne ® included in 
service since April 2015) No medication supplied  988  (2.7) 990 (2.6) 830 (2.3) 737 (2.1) 627  (1.8) 4,172 (2.4)
Sexual health clinic - - - - 1,545 (17.8) 6,057 (17.0)
6,802 (19.2)
14,404 (18.0)Referral to another agency 
(data available since April 
2015) General Practitioner (GP) - - - - 1,043 (12.0) 4,772 (13.4) 4,684 (13.2) 10,499 (13.1)
Out of hours (OOH) - - - - 0 (0.0) 0 (0.0) 26 (0.1) 26 -
Another pharmacy - - - - 0 (0.0) 1 (0.0) 24 (0.1) 25 -
Accident & Emergency (A&E) - - - - 0 (0.0) 0 (0.0) 2 (0.0) 2 -
No referral - - - - 6,080 (70.1) 24,902 (69.7) 23,978 (67.5) 54,960 (68.8)
Total 79,916
Yes 28,758 (77.6) 29,470 (78.8) 27,401 (76.9) 28,526 (79.8) 29,396 (82.8) 143,551 (79.2)Further sexual health and 
contraception information 
provided No 8,320 (22.4) 7,946 (21.2) 8,216 (23.1) 7,206 (20.2) 6,120 (17.2) 37,808 (20.8)
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* Overall percentages may not add to 100 due to rounding
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Table 2: Rate of consultations per age group, when numbers were standardized using data 
for estimated population in Wales (15) (data available for 2012-16).
Age group Average population 
Average number of users 
per year
Rate (users/100 
population)
13-15 103,855 1,074 1.0
16-19 153,323 8,420 5.5
20-24 211,100 10,760 5.1
25-29 200,900 6,830 3.4
30-39 358,000 6,822 1.9
40+ 818,100 2,155 0.3
Day and time after UPSI EC service was accessed
There was a statistically significant difference on number of consultations with day of week 
(Kruskal Wallis test, p<0.001, CI 95%). More than a quarter of the consultations were 
conducted on a Monday (25.8%) and just under a quarter of consultations (24.6%) during 
the weekend (Figure 2). An association was observed between the time since UPSI and the 
day on which the service was accessed (X2(18) = 16292.327, p<0.001). Consultations within 
25-48 hours of UPSI were more likely to happen on Mondays and Tuesdays, and for 49-120
hours since UPSI on Mondays, Tuesdays and Wednesdays (Supplementary Table 1). In the
5-year period, more than two thirds of requests made through the EC service took place
within 24 hours of UPSI (67.5%). Requests made more than 49 hours after UPSI increased
from 6.0% to 10.5% of total annual consultations.
Reasons for requesting EC 
Over the 5-year period, almost half (47.9%) of requests made through the EC service were 
because no contraception had been used. EC requests resulting from barrier contraception 
failure decreased from 45.8% to 37.9% over the study period (Table 1), p-value for trend 
0.002 (Figure 3). A statistically significant association was found between EC request 
reasons and the age group of EC service users (X2(15) = 989.271, p<0.001).  There was a 
strong negative association between EC requests due to barrier contraception failure and 
patients aged 24 or under, and a strong positive association for those aged over 25. A strong 
positive association was observed for no contraception use and teenagers, and reporting of 
missed contraceptive pills and women between 20-29 years old (Supplementary Table 2).
Regular contraception use
Over the 5-years, the percentage of consultations conducted with patients who used regular 
contraception decreased from 44.2% to 33.9% (Table 1), p-value for trend <0.001 
(Supplementary Figure 3). A statistically significant association was found between regular 
contraception use and the age group of EC service users (X2(5) = 724.655, p<0.001). 
Teenagers and women over 40 were more likely to not use regular contraception 
(Supplementary Table 3). 
Service outcomes
Levonorgestrel was supplied in 96.7% of the consultations; 2.4% of consultations resulted in 
no medication being supplied (Table 1). Since 2015, levonorgestrel and ulipristal were 
supplied in 95.8% and 2.2% of consultations respectively. The proportion of ulipristal 
supplies was similar to the rate of late presentations (2.2% and 1.5% respectively). Only 
0.1% of users (n=187) failed to access the service within 120 hours following UPSI. No data 
was available to identify reasons for delayed access.
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Further sexual health and contraception counselling was provided in 79.2% and referral to 
another agency in 31.3% of EC consultations; both increased with time (Pearson’s 
correlation r=0.7, p<0.001 and r=0.56, p=0.002 respectively, supplementary Figures 4 and 
5).
Discussion
This study describes long term trends in the use of CP EC services using data from all NHS 
funded EC consultations in CPs in Wales over a five year period, and provides the first 
insight into the changing pattern of CP EC service use over time.   We found substantial 
numbers of EC consultations took place in CPs in each year of the study but with indications 
that numbers of consultations were declining over time.  By the end of year five, the annual 
number of consultations was 4.2% lower than at the end of year one.  However, data 
indicate the decline took place between years two and three with little change in consultation 
numbers in the most recent three year period.  Previous studies report concern of an 
increasing demand for EC when introducing a PGD (11); we found no evidence to support 
concerns that routine access to EC from CP leads to increased use over time.  Over 97% of 
consultations resulted in the supply of EC. A small reduction in the proportion of 
consultations resulting in supply of levonorgestrel was observed following the inclusion of 
ulipristal acetate, as a treatment option for service users presenting more than 72 hours 
following UPSI, in April 2015.
Most EC consultations took place with 20-24 year-olds, however use in this group 
represented less than 30% of all EC consultations with the service accessed by large 
numbers of service users of all ages . This suggests the service is helping meet the sexual 
health needs of many women regardless of age. Despite a lower number and proportion of 
consultations amongst 16-19-year-olds, age standardized rates demonstrate this group were 
the most frequent users of the CP service over the study period.  This finding supports the 
role of the CP EC service as part of a wider teenage pregnancy strategy.  Access to free of 
charge EC, which is especially relevant to young users, may have contributed to uptake. (10) 
Despite use being high in teenagers aged 16-19, in teenagers aged 13-15 it was very low; 
this must be interpreted carefully as age may have been deliberately concealed due to 
negative societal perceptions of sexual intercourse in those under the legal age of consent.   
Access to EC from CPs has coincided with decreased rates of abortion (16) and live births to 
teenage mothers in Wales. (17) Whilst the rate of abortions in the 20-24-year-old age group 
has decreased (16), it remains higher than in other age groups, following the same pattern 
as the number of EC consultations during the study period. This may suggest this group who 
would have been teenagers at the start of the study period and were the target of measures 
to improve availability of EC, continue to use EC as a means of contraception in later life. 
Further work may be required to promote routine contraception amongst this age group.
Around 25% of all EC consultations occurred on a Monday, with Tuesday and Saturday (at 
~15%) the next most popular days.  The lowest proportion of consultations was observed on 
Sunday (9.5%).   This, alongside the finding that girls and women using the CP EC service 
on Monday, Tuesday and Wednesday were more likely to have had UPSI more than 48 
hours earlier, suggest poorer access to EC over the weekend.  Prompt access is of clinical 
significance, as the sooner EC is taken the more effective it is. (1) Previous studies found 
that access was a barrier to EC use and that the longer opening hours, weekend openings 
and more accessible locations of pharmacies allowed most users to access EC within 24 
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
10
Page 11 of 22
hours, (9,12, 18,19) our study demonstrates that there remain barriers to access on Sunday.  
Possible reason for this are fewer pharmacies being open and shorter opening times 
amongst those pharmacies that are open.  A focussed review of accessibility of EC service 
on Sunday would be beneficial for service commissioners, to explore whether other 
determinants, for example the absence of a pharmacist accredited to provide the EC service, 
contributed to this finding. 
The reasons for requesting EC differ with age. Women under 19 and over 40 were more 
likely not to use regular contraception although we found differences between these groups 
in relation to UPSI. In general, those under 19 were more likely to report not using any form 
of contraception; those over 40 were more likely to report failure of barrier contraception. Our 
data indicate women aged 20-29 were most likely to use regular contraception, requesting 
EC because they missed doses. Reasons older women are not using regular contraception 
may be attributable to physiological changes such as the menopause, or perceived lack of 
need after having children. (20) Trip et al found that younger users may be less likely to use 
regular contraception due to a lack of ability to find suitable contraception. (21) Firman et al 
explored the impact of nature and duration of relationship on preferred method of 
contraception and established that barrier methods were higher in short-term relationships 
among younger population. (22) Pregnancy ‘risk’ perception and personal invulnerability may 
be potential factors influencing the use/non-use of contraception during sexual intercourse. 
(23,24) A large study amongst young people in Britain aged 16-24 highlighted the need for 
more information on ‘safer’ sex, contraception/birth control, correct condom uses and 
sexually transmitted infection. (25) Geary et al reported that young people favour obtaining 
sexual information and contraception from a healthcare rather than an online source. (26f) 
Findings of this study support the expressed need for improved sex education in schools 
alongside greater involvement from healthcare professionals to raise awareness on 
contraception use.
This is the largest ever study of CP provided EC services and the first to examine changes in 
service use over time.  The study size and duration mean our results are likely to be 
generalizable.  Restrictions on information recorded in consultations (including data format) 
and tracing missing information were limitations. However, we accounted for the small 
number of consultations missing information on age of users and hence it is unlikely that this 
affects the results. A degree of self-reporting bias from some service users should be 
considered due to the sensitivity of the topic. The inability to identify repeat EC service users 
prevented quantification of the actual number of women using the EC service and 
investigation of changes in contraceptive behaviour over time. Data linkage to enable 
anonymised identification of multiple consultations by service users should be considered to 
improve future analyses.  
This study suggests improved access to EC, as part of the multifaceted approach set out in 
Wales’ sexual health action plan of 2010 (27) is contributing to a positive and sustained 
effect towards the root causes of teenage pregnancy. The finding that provision of further 
sexual health and contraception counselling by pharmacists increased over the study period, 
in line with the original aims of the EC service, adds further support for extending the role of 
CPs.  Our findings support CP extended roles, for example in the provision of routine oral 
contraception, as described in the 2017-18 report on sexual health in Wales (28) and 
reinforced by Parsons et al (29) and the results of the third National Survey of Sexual 
Attitudes and Lifestyles (30).
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Figure 1: A flowchart illustrating the study methodology, in accordance with RECORD 
guidelines (13)
Figure 2: A graph illustrating the percentage (%) of consultations that took place within the 
stated time frames after UnProtected Sexual Intercourse (UPSI) for each day of the week 
(information available for n = 181,172). The proportion of consultations for the different days 
of the week is presented in brackets.
Figure 3: A graph illustrating the numbers of consultations for the different reasons 
Emergency Contraception (EC) was requested, per reporting period (information available 
for n = 181,359). P-values for trend lines have been calculated with 95% confidence 
intervals. 
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Figure 2: A graph illustrating the percentage (%) of consultations that took place within the stated time 
frames after UnProtected Sexual Intercourse (UPSI) for each day of the week (information available for n = 
181,172). The proportion of consultations for the different days of the week is presented in brackets. 
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Figure 3: A graph illustrating the numbers of consultations for the different reasons Emergency 
Contraception (EC) was requested, per reporting period (information available for n = 181,359). P-values for 
trend lines have been calculated with 95% confidence intervals. 
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1Supplementary Table 1: Z-scores from cross-tabulation between day of Emergency Contraception (EC) request and time since UnProtected 
Sexual Intercourse (UPSI)
Supplementary Table 2: Z-scores from cross-tabulation of reason for Emergency Contraception (EC) request and age group of users 
accessing the EC service
Age group (years)
13-15 16-19 20-24 25-29 30-39 40+
Reason for EC Request Barrier contraception failure
-4.7 -10.3 -3.0 2.8 9.6 8.0
No contraception used 10.0 9.5 -1.4 -4.4 -6.8 -2.6
Missed pill -12.3 .5 9.7 4.1 -5.5 -11.2
Time Since UPSI
Day of EC 
request
0-24h 25-48h 49-120h 120+h
Sunday 18.4 -17.4 -22.8 -2.5
Monday -47.6 71.0 14.1 -1.1
Tuesday -19.2 8.0 42.4 -.9
Wednesday 6.0 -14.5 7.9 .7
Thursday 16.3 -21.2 -10.5 1.0
Friday 15.5 -16.9 -16.0 2.2
Saturday 33.5 -41.0 -26.0 .9
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2Supplementary Table 3: Z-scores from cross-tabulation between regular contraception use and age group of users accessing the 
Emergency Contraception service
 Using Regular 
Contraception
Age group (years)
13-15 16-19 20-24 25-29 30-39 40+
No 13.2 2.3 -6.6 -4.3 1.0 6.6
Yes -16.4 -2.8 8.1 5.3 -1.3 -8.2
2012 2013 2014 2015 2016 2017
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r=-0.41, p=0.001,
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3Supplementary Figure 1: Relationship between time and absolute number of requests made through the EC service in Wales
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4Supplementary Figure 2: A graph illustrating the proportion (%) of yearly consultations for three time periods since UnProtected Sexual 
Intercourse (UPSI) (information available for n = 181,359 consultations) against the reporting period. P-values for trend lines have been 
calculated with 95% confidence intervals.  
Supplementary Figure 3: A graph illustrating the proportion (%) of yearly consultations where regular contraception was used (information 
available for n = 181,359 consultations). P-values for trend lines have been calculated with 95% confidence intervals.
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5Supplementary Figure 4: Relationship between time and the percentage of EC requests involving further sexual health and contraception 
counselling from pharmacists during consultations
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6Supplementary Figure 5: Relationship between time and percentage of requests made through the EC service in Wales referred to another 
agency (sexual health clinic, GP, out of hours, another pharmacy or A&E), from April 2015 since the information started being recorded
2015 2016 2017
25.0%
27.0%
29.0%
31.0%
33.0%
35.0%
37.0%
Year
Pe
rc
en
ta
ge
 o
f  
EC
 re
qu
es
ts
 
r=0.56, p=0.002,
R2=0.3143
Page 23 of 22
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
